The COLOCARE study

A paradigm of transdisciplinary science in colorectal cancer outcomes

Cornelia M. Ulrich, Biljana Gigic, Jurgen Bohm, Jennifer Ose, Richard Viskochil, Martin Schneider, Graham A. Colditz, Jane C. Figueiredo, William M. Grady, Christopher I. Li, David Shibata, Erin M. Siegel, Adetunji T. Toriola, Alexis Ulrich

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Colorectal cancer is a leading cause of cancer death. Biomarkers to predict treatment outcomes are needed, as is evidence whether postdiagnosis diet and lifestyle can affect well-being and clinical outcomes. The international ColoCare Consortium aims to identify new biologic markers (e.g., metabolomic, transcriptomic, metagenomic, genetic, epigenetic, proteomic markers) that predict clinical outcomes, and to characterize associations between modifiable risk factors (e.g., diet, supplement use, physical activity) with short-term and long-term patient-reported and clinical outcomes among patients with colorectal cancer. Methods/Results: ColoCare is recruiting newly diagnosed patients with colorectal cancer across six sites in the United States and one site in Germany. As of April 2018, we have recruited >2,000 patients across all sites. Our projected enrollment is >4,000 multiethnic patients with colorectal cancer. The study includes uniformly collected, comprehensive sets of data and biospecimens at multiple time points up to 5 years after diagnosis. Treatment and clinical data are abstracted from medical records and centrally harmonized. Biospecimens are archived according to standardized procedures. Our initial studies demonstrated metabolic differences in adipose tissue types. We further reported on associations of biological factors (e.g., inflammation, DNA methylation, metabolomics) with lifestyle factors (e.g., adiposity, smoking, physical activity, dietary supplement use) or joint associations with clinical outcomes. Conclusions: ColoCare is a consortium for the investigation of multilevel factors relevant to colorectal cancer survivorship. Impact: The combination of a comprehensive set of biospecimens collected at multiple time points, jointly with detailed assessments of health behaviors and other prognostic factors, results in a unique resource that facilitates wide-ranging, innovative, and impactful research on colorectal cancer.

Original languageEnglish (US)
Pages (from-to)591-601
Number of pages11
JournalCancer Epidemiology Biomarkers and Prevention
Volume28
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Colorectal Neoplasms
Metabolomics
Biomarkers
Life Style
Exercise
Diet
Metagenomics
Health Behavior
Adiposity
Biological Factors
DNA Methylation
Dietary Supplements
Epigenomics
Proteomics
Medical Records
Germany
Adipose Tissue
Cause of Death
Survival Rate
Smoking

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Oncology

Cite this

The COLOCARE study : A paradigm of transdisciplinary science in colorectal cancer outcomes. / Ulrich, Cornelia M.; Gigic, Biljana; Bohm, Jurgen; Ose, Jennifer; Viskochil, Richard; Schneider, Martin; Colditz, Graham A.; Figueiredo, Jane C.; Grady, William M.; Li, Christopher I.; Shibata, David; Siegel, Erin M.; Toriola, Adetunji T.; Ulrich, Alexis.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 28, No. 3, 01.03.2019, p. 591-601.

Research output: Contribution to journalArticle

Ulrich, CM, Gigic, B, Bohm, J, Ose, J, Viskochil, R, Schneider, M, Colditz, GA, Figueiredo, JC, Grady, WM, Li, CI, Shibata, D, Siegel, EM, Toriola, AT & Ulrich, A 2019, 'The COLOCARE study: A paradigm of transdisciplinary science in colorectal cancer outcomes', Cancer Epidemiology Biomarkers and Prevention, vol. 28, no. 3, pp. 591-601. https://doi.org/10.1158/1055-9965.EPI-18-0773
Ulrich, Cornelia M. ; Gigic, Biljana ; Bohm, Jurgen ; Ose, Jennifer ; Viskochil, Richard ; Schneider, Martin ; Colditz, Graham A. ; Figueiredo, Jane C. ; Grady, William M. ; Li, Christopher I. ; Shibata, David ; Siegel, Erin M. ; Toriola, Adetunji T. ; Ulrich, Alexis. / The COLOCARE study : A paradigm of transdisciplinary science in colorectal cancer outcomes. In: Cancer Epidemiology Biomarkers and Prevention. 2019 ; Vol. 28, No. 3. pp. 591-601.
@article{704a05034b1f478486a6e1880120a025,
title = "The COLOCARE study: A paradigm of transdisciplinary science in colorectal cancer outcomes",
abstract = "Background: Colorectal cancer is a leading cause of cancer death. Biomarkers to predict treatment outcomes are needed, as is evidence whether postdiagnosis diet and lifestyle can affect well-being and clinical outcomes. The international ColoCare Consortium aims to identify new biologic markers (e.g., metabolomic, transcriptomic, metagenomic, genetic, epigenetic, proteomic markers) that predict clinical outcomes, and to characterize associations between modifiable risk factors (e.g., diet, supplement use, physical activity) with short-term and long-term patient-reported and clinical outcomes among patients with colorectal cancer. Methods/Results: ColoCare is recruiting newly diagnosed patients with colorectal cancer across six sites in the United States and one site in Germany. As of April 2018, we have recruited >2,000 patients across all sites. Our projected enrollment is >4,000 multiethnic patients with colorectal cancer. The study includes uniformly collected, comprehensive sets of data and biospecimens at multiple time points up to 5 years after diagnosis. Treatment and clinical data are abstracted from medical records and centrally harmonized. Biospecimens are archived according to standardized procedures. Our initial studies demonstrated metabolic differences in adipose tissue types. We further reported on associations of biological factors (e.g., inflammation, DNA methylation, metabolomics) with lifestyle factors (e.g., adiposity, smoking, physical activity, dietary supplement use) or joint associations with clinical outcomes. Conclusions: ColoCare is a consortium for the investigation of multilevel factors relevant to colorectal cancer survivorship. Impact: The combination of a comprehensive set of biospecimens collected at multiple time points, jointly with detailed assessments of health behaviors and other prognostic factors, results in a unique resource that facilitates wide-ranging, innovative, and impactful research on colorectal cancer.",
author = "Ulrich, {Cornelia M.} and Biljana Gigic and Jurgen Bohm and Jennifer Ose and Richard Viskochil and Martin Schneider and Colditz, {Graham A.} and Figueiredo, {Jane C.} and Grady, {William M.} and Li, {Christopher I.} and David Shibata and Siegel, {Erin M.} and Toriola, {Adetunji T.} and Alexis Ulrich",
year = "2019",
month = "3",
day = "1",
doi = "10.1158/1055-9965.EPI-18-0773",
language = "English (US)",
volume = "28",
pages = "591--601",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - The COLOCARE study

T2 - A paradigm of transdisciplinary science in colorectal cancer outcomes

AU - Ulrich, Cornelia M.

AU - Gigic, Biljana

AU - Bohm, Jurgen

AU - Ose, Jennifer

AU - Viskochil, Richard

AU - Schneider, Martin

AU - Colditz, Graham A.

AU - Figueiredo, Jane C.

AU - Grady, William M.

AU - Li, Christopher I.

AU - Shibata, David

AU - Siegel, Erin M.

AU - Toriola, Adetunji T.

AU - Ulrich, Alexis

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background: Colorectal cancer is a leading cause of cancer death. Biomarkers to predict treatment outcomes are needed, as is evidence whether postdiagnosis diet and lifestyle can affect well-being and clinical outcomes. The international ColoCare Consortium aims to identify new biologic markers (e.g., metabolomic, transcriptomic, metagenomic, genetic, epigenetic, proteomic markers) that predict clinical outcomes, and to characterize associations between modifiable risk factors (e.g., diet, supplement use, physical activity) with short-term and long-term patient-reported and clinical outcomes among patients with colorectal cancer. Methods/Results: ColoCare is recruiting newly diagnosed patients with colorectal cancer across six sites in the United States and one site in Germany. As of April 2018, we have recruited >2,000 patients across all sites. Our projected enrollment is >4,000 multiethnic patients with colorectal cancer. The study includes uniformly collected, comprehensive sets of data and biospecimens at multiple time points up to 5 years after diagnosis. Treatment and clinical data are abstracted from medical records and centrally harmonized. Biospecimens are archived according to standardized procedures. Our initial studies demonstrated metabolic differences in adipose tissue types. We further reported on associations of biological factors (e.g., inflammation, DNA methylation, metabolomics) with lifestyle factors (e.g., adiposity, smoking, physical activity, dietary supplement use) or joint associations with clinical outcomes. Conclusions: ColoCare is a consortium for the investigation of multilevel factors relevant to colorectal cancer survivorship. Impact: The combination of a comprehensive set of biospecimens collected at multiple time points, jointly with detailed assessments of health behaviors and other prognostic factors, results in a unique resource that facilitates wide-ranging, innovative, and impactful research on colorectal cancer.

AB - Background: Colorectal cancer is a leading cause of cancer death. Biomarkers to predict treatment outcomes are needed, as is evidence whether postdiagnosis diet and lifestyle can affect well-being and clinical outcomes. The international ColoCare Consortium aims to identify new biologic markers (e.g., metabolomic, transcriptomic, metagenomic, genetic, epigenetic, proteomic markers) that predict clinical outcomes, and to characterize associations between modifiable risk factors (e.g., diet, supplement use, physical activity) with short-term and long-term patient-reported and clinical outcomes among patients with colorectal cancer. Methods/Results: ColoCare is recruiting newly diagnosed patients with colorectal cancer across six sites in the United States and one site in Germany. As of April 2018, we have recruited >2,000 patients across all sites. Our projected enrollment is >4,000 multiethnic patients with colorectal cancer. The study includes uniformly collected, comprehensive sets of data and biospecimens at multiple time points up to 5 years after diagnosis. Treatment and clinical data are abstracted from medical records and centrally harmonized. Biospecimens are archived according to standardized procedures. Our initial studies demonstrated metabolic differences in adipose tissue types. We further reported on associations of biological factors (e.g., inflammation, DNA methylation, metabolomics) with lifestyle factors (e.g., adiposity, smoking, physical activity, dietary supplement use) or joint associations with clinical outcomes. Conclusions: ColoCare is a consortium for the investigation of multilevel factors relevant to colorectal cancer survivorship. Impact: The combination of a comprehensive set of biospecimens collected at multiple time points, jointly with detailed assessments of health behaviors and other prognostic factors, results in a unique resource that facilitates wide-ranging, innovative, and impactful research on colorectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=85062408204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062408204&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-18-0773

DO - 10.1158/1055-9965.EPI-18-0773

M3 - Article

VL - 28

SP - 591

EP - 601

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 3

ER -